Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Assertio Therapeutics Inc (ASRT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ASRT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.62
1 Year Target Price $2.62
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 1.18% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 78.38M USD | Price to earnings Ratio - | 1Y Target Price 2.62 |
Price to earnings Ratio - | 1Y Target Price 2.62 | ||
Volume (30-day avg) 4 | Beta 0.28 | 52 Weeks Range 0.51 - 1.38 | Updated Date 08/15/2025 |
52 Weeks Range 0.51 - 1.38 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.08 | Actual 0.02 |
Profitability
Profit Margin -36.97% | Operating Margin (TTM) -27.5% |
Management Effectiveness
Return on Assets (TTM) -7.78% | Return on Equity (TTM) -38.4% |
Valuation
Trailing PE - | Forward PE 14.99 | Enterprise Value 19492695 | Price to Sales(TTM) 0.67 |
Enterprise Value 19492695 | Price to Sales(TTM) 0.67 | ||
Enterprise Value to Revenue 0.17 | Enterprise Value to EBITDA 4.03 | Shares Outstanding 95780704 | Shares Floating 85953534 |
Shares Outstanding 95780704 | Shares Floating 85953534 | ||
Percent Insiders 2.51 | Percent Institutions 27.23 |
Upturn AI SWOT
Assertio Therapeutics Inc
Company Overview
History and Background
Assertio Therapeutics Inc., formerly Depomed, Inc., focuses on acquiring, developing, and commercializing pharmaceutical products. Founded in 1995, the company initially focused on novel drug delivery technologies. Over time, it shifted towards acquiring and managing established branded pharmaceutical products.
Core Business Areas
- Neurology: Products focused on treating neurological conditions, including pain management.
Leadership and Structure
Dan Peisert is the CEO. The organizational structure is typical for a pharmaceutical company, with departments focused on sales, marketing, research and development, and finance.
Top Products and Market Share
Key Offerings
- Indocin: Indocin is a nonsteroidal anti-inflammatory drug (NSAID) used to treat moderate to severe inflammation due to a variety of causes, including arthritis, gout, bursitis, and tendinitis. Competitors include other NSAIDs from companies like Pfizer (PFE) and AbbVie (ABBV).
- Cambia: Cambia (diclofenac potassium for oral solution) is an NSAID for the acute treatment of migraine attacks with or without aura in adults. Competitors include other migraine medications like triptans from companies like Teva Pharmaceutical Industries (TEVA) and Novartis (NVS).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with a focus on research and development, manufacturing, marketing, and sales of pharmaceutical products. Key trends include increasing drug prices, generic competition, and regulatory scrutiny.
Positioning
Assertio is positioned as a specialty pharmaceutical company focused on acquiring and commercializing established branded products, a niche that requires efficient operations and strong sales/marketing capabilities.
Total Addressable Market (TAM)
TAM is estimated in the billions. Assertio occupies a small portion of the TAM. Positioned to grow in its areas of focus
Upturn SWOT Analysis
Strengths
- Established product portfolio
- Experienced management team
- Focus on niche markets
- Strong sales and marketing capabilities
Weaknesses
- Reliance on a limited number of products
- Vulnerability to generic competition
- Potential regulatory risks
- High debt levels
Opportunities
- Acquisition of complementary products
- Expansion into new markets
- Development of new formulations
- Partnerships and collaborations
Threats
- Increased generic competition
- Pricing pressures
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- TEVA
- PFE
- ABBV
- NVS
Competitive Landscape
Assertio's advantage lies in its focus on niche products and efficient operations. Disadvantages include limited product portfolio and vulnerability to generic competition compared to larger, more diversified competitors.
Growth Trajectory and Initiatives
Historical Growth: Growth data needs to be obtained dynamically and assessed for past trends.
Future Projections: Future projections require analyst estimates, not available for hardcoding.
Recent Initiatives: Assertio has recently focused on streamlining operations and debt reduction.
Summary
Assertio Therapeutics operates in a competitive pharmaceutical market, showing strength in niche product focus and efficient operations. Its limited product portfolio and exposure to generic competition remain key weaknesses. Strategic acquisitions and debt reduction are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Assertio Therapeutics Inc
Exchange NASDAQ | Headquaters Lake Forest, IL, United States | ||
IPO Launch date 1997-11-05 | CEO & Director Mr. Brendan P. O'Grady | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 58 | Website https://www.assertiotx.com |
Full time employees 58 | Website https://www.assertiotx.com | ||
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.